<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108380</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-GS-HBP3</org_study_id>
    <secondary_id>B-0901-068-003</secondary_id>
    <nct_id>NCT01108380</nct_id>
  </id_info>
  <brief_title>Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells</brief_title>
  <official_title>Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells Transplantation in the Patient Needed Extensive Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patient with liver cirrhosis who need to right or extended right hepatectomy, we will
      treat with autologous peripheral stem cells transplantation to facilitate liver regeneration.
      We will asses liver regeneration by evaluation of liver volume and liver function test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Patients: 30 patients (10 patients in each 3 group)

        2. Indication:

             -  Patients with Primary hepatocellular carcinoma combined liver cirrhosis (Hepatitis
                B, C, Non-B Non-C)

             -  Planned to right hepatectomy or extended right hepatectomy

             -  Patients who need right portal vein embolization due to insufficient expected
                remnant liver volume (&lt; 40%) or severe hepatic dysfunction(ICGR15&gt;10%)

             -  Child A classification

             -  ICG R15 &lt; 25%

             -  Age : 20 - 70 years old

             -  Expected life period &gt; 3months

             -  The patients who agreed to this study.

        3. Contraindication

             -  Patients who planned liver transplantation

             -  Age &lt;20 or &gt;70 years old

             -  Pregnant women

             -  Patients on acute infection

             -  Acute hepatic failure

             -  Child class B or C

             -  Heart failure

             -  Existence of bleeding tendency : platelet &lt; 30,000, INR &gt; 2.2, Cr &gt;2.5

             -  Patients who did not agree to this study.

        4. Allocation: We will allocate patients randomly to three group including control group.

        5. Methods

             -  Group 1: 4 days injection of G-CSF -&gt; Plasma pheresis, Selection of CD34 cell -&gt;
                Right portal vein embolization and infusion of CD34 cell into left portal vein.

             -  Group 2: 4 days injection of G-CSF -&gt; Plasma pheresis -&gt; Right portal vein
                embolization and infusion of mononuclear cell into left portal vein.

             -  Group 3 (control): Right portal vein embolization

           ( -&gt; after 4 weeks, operation will be performed)

        6. Evaluation: Change of liver volume, liver function test before and after portal vein
           embolization
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy, short term outcome</measure>
    <time_frame>4 weeks after procedure</time_frame>
    <description>After portal vein embolization, we will compare liver volume by CT and liver function test by blood test in 3 groups. (Second and forth week)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and efficacy.</measure>
    <time_frame>12 weeks</time_frame>
    <description>After 4 weeks of portal vein embolization, hepatectomy woul be performed in indicated patients. After hepatectomy, until 12 weeks, we will compare remnant liver volume by CT and liver function test by blood test.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>1. CD34</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)
On 5th day, plasmapheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)
CD 34 cells will be selected by CliniMACS (Miltenyi Biotec, Bergisch- Gladbach, Germany) (at least 1x10(7) of CD 34 cell)
In same day, right portal vein embolization with infusion of CD 34 cells into left portal vein will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Mononucelar cell</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)
On 5th day, plasma pheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)
In same day, right portal vein embolization with infusion of mononuclear cells into left portal vein will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Without infusion of G-CSF, patients will be performed just right portal vein embolization</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasma pheresis, Right portal vein embolization</intervention_name>
    <description>Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.
Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam.</description>
    <arm_group_label>1. CD34</arm_group_label>
    <arm_group_label>2. Mononucelar cell</arm_group_label>
    <arm_group_label>3. Control</arm_group_label>
    <other_name>COBE BCT Inc : for plasmapheresis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with Primary hepatocellular carcinoma combined liver cirrhosis (Hepatitis B,
             C, Non-B Non-C)

          2. Planned to right hepatectomy or extended right hepatectomy

          3. Patients who need right portal vein embolization due to unsufficient expected remnant
             liver volume (&lt; 40%) or severe hepatic dysfunction (ICG R15 &gt; 10%)

          4. Child A classification

          5. ICG R15 &lt; 25%

          6. Age: 20 - 70 years old

          7. Expected life period &gt; 3months

          8. The patients who agreed to this study

        Exclusion Criteria:

          1. Patients who planned liver transplantation

          2. Age &lt; 20 or &gt; 70 years old

          3. Pregnant women

          4. Patients on acute infection

          5. Acute hepatic failure

          6. Child class B or C

          7. Heart failure

          8. Existence of bleeding tendency : platelet &lt; 30,000, INR &gt; 2.2, Cr &gt;2.5

          9. Patients who did not agree to this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho-Seong Han, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chairman of surgery, Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ho-Seong Han, PhD</last_name>
    <phone>82-31-787-7099</phone>
    <email>hanhs@snubh.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keun Soo Ahn, MD</last_name>
    <phone>82-31-787-7099</phone>
    <email>ahnks@snubh.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ho-Seong Han</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2010</study_first_posted>
  <last_update_submitted>December 14, 2010</last_update_submitted>
  <last_update_submitted_qc>December 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ho-Seong Han. Chairman of surgery department. Seoul National University Bundang Hospital</name_title>
    <organization>Surgery department</organization>
  </responsible_party>
  <keyword>Liver cirrhosis</keyword>
  <keyword>liver regeneration</keyword>
  <keyword>liver volume</keyword>
  <keyword>liver function</keyword>
  <keyword>hepatocellular carcinoma, extensive</keyword>
  <keyword>hepatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>December 5, 2013</submitted>
    <returned>January 21, 2014</returned>
    <submitted>May 19, 2015</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>June 4, 2015</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>June 8, 2015</submitted>
    <returned>June 29, 2015</returned>
    <submitted>April 27, 2016</submitted>
    <returned>June 2, 2016</returned>
    <submitted>October 27, 2016</submitted>
    <returned>December 27, 2016</returned>
    <submitted>January 8, 2017</submitted>
    <returned>February 24, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

